Signe Stensen
Overview
Explore the profile of Signe Stensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verma S, Emerson S, Plutzky J, Kahn S, Stensen S, Weeke P, et al.
J Am Coll Cardiol
. 2024 Nov;
85(5):541-545.
PMID: 39566870
No abstract available.
2.
Hansen L, Gasbjerg L, Bronden A, Dalsgaard N, Bahne E, Stensen S, et al.
Eur J Endocrinol
. 2024 Jul;
191(2):192-203.
PMID: 39049802
Aims: Although metformin is widely used for treatment of type 2 diabetes (T2D), its glucose-lowering mechanism remains unclear. Using the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) antagonist exendin(9-39)NH2, we tested...
3.
Vilsboll T, Gribsholt S, Jorgensen N, Andreassen P, Nielsen P, Yssing C, et al.
Diabetes Obes Metab
. 2023 Jun;
25(9):2595-2604.
PMID: 37272318
Aim: Weight bias, stigma and discrimination are pervasive in the health care system and society and may result in biased treatment of people living with obesity (PwO). We aimed to...
4.
Krogh L, Henriksen K, Stensen S, Skov-Jeppesen K, Bergmann N, Storling J, et al.
Eur J Endocrinol
. 2023 Jan;
188(1).
PMID: 36651162
Objective: The gut hormone glucose-dependent insulinotropic polypeptide (GIP) is an important regulator of glucose and bone metabolism. In rodents, the naturally occurring GIP variant, GIP(1-30)NH2, has shown similar effects as...
5.
Stensen S, Gasbjerg L, Rosenkilde M, Vilsboll T, Holst J, Hartmann B, et al.
Diabetes
. 2022 Jul;
71(10):2209-2221.
PMID: 35796651
Dipeptidyl peptidase 4 (DPP-4) degrades the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibitors improve glycemic control in type 2 diabetes, but the importance of protecting...
6.
Stensen S, Krogh L, Sparre-Ulrich A, Dela F, Hartmann B, Vilsboll T, et al.
Diabetes Obes Metab
. 2022 May;
24(9):1882-1887.
PMID: 35491518
No abstract available.
7.
Stensen S, Gasbjerg L, Krogh L, Skov-Jeppesen K, Sparre-Ulrich A, Jensen M, et al.
Eur J Endocrinol
. 2021 Apr;
185(1):33-45.
PMID: 33886495
Objective: The insulinotropic effect of exogenous, intravenously infused glucose-dependent insulinotropic polypeptide (GIP) is impaired in patients with type 2 diabetes. We evaluated the effects of endogenous GIP in relation to...
8.
Dalsgaard N, Gasbjerg L, Hansen L, Hansen N, Stensen S, Hartmann B, et al.
Eur J Endocrinol
. 2021 Jan;
184(3):383-394.
PMID: 33449919
Aims: The alpha-glucosidase inhibitor acarbose is believed to reduce plasma glucose by delaying hydrolysis of carbohydrates. Acarbose-induced transfer of carbohydrates to the distal parts of the intestine increases circulating glucagon-like...
9.
Gasbjerg L, Bari E, Stensen S, Hoe B, Lanng A, Mathiesen D, et al.
Diabetes Obes Metab
. 2020 Sep;
23(1):68-74.
PMID: 32886401
The glucose-dependent insulinotropic polypeptide (GIP) fragment GIP(3-30)NH is a selective, competitive GIP receptor antagonist, and doses of 800 to 1200 pmol/kg/min inhibit GIP-induced potentiation of glucose-stimulated insulin secretion by >80%...
10.
Helsted M, Gasbjerg L, Lanng A, Bergmann N, Stensen S, Hartmann B, et al.
Bone
. 2020 Jul;
140:115553.
PMID: 32730920
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are well known for their insulinotropic effects and they are thought to affect bone homeostasis as mediators in...